Detection of rare tumor cells in stem cell collections is not performed routinely due to the lack of reproducible and reliable techniques with high specificity and sensitivity. The number of carcinoma cells in PBSC from patients with breast cancer should range between 2 and 3500 tumor cells in 10 6 mononuclear cells (MNC). [6] [7] [8] Immunocytochemistry (ICC) and RT-PCR are the most frequently used techniques for detection of epithelial tumor cells. RT-PCR is claimed to be a more sensitive and less labor-intensive technique to detect rare tumor cells as compared to ICC. In contrast to some hematological malignancies or to Ewing's sarcoma, no common tumor-specific DNA rearrangements have been described in carcinomas that could be amplified by PCR.
For breast cancer, several genes presumed to be specifically expressed by circulating malignant breast cells and not by hematological cells have been exploited to detect breast tumor cell contamination in hematological tissues including cytokeratin 19 (CK19), 9, 10, 11, 12 carcinoembryonic antigen (CEA) [13] [14] [15] [16] [17] [18] and Mucin-1 (Muc-1). 19 Interested by the significance of contaminating tumor cells in leukapheresis products of breast cancer patients, we firstly tested sensitivity and specificity of RT-PCR in PBMC for those three marker genes.
Although CEA RT-PCR gave the best specificity on blood obtained from healthy individuals, it was unreliable on leukapheresis products obtained from breast cancer patients. The extremely high CEA RT-PCR positivity rate in leukapheresis products was not correlated with tumor cell detection by ICC. Specificity was lost due to induction of CEA expression in PBSC by granulocyte colonystimulating factor (G-CSF).
Materials and methods

Peripheral blood and leukapheresis products
Eighty-three peripheral blood samples were analyzed; 47 from healthy individuals, 21 from breast cancer patients before surgical tumor resection, 10 from breast cancer patients following hematological recovery from adjuvant chemotherapy, four from cancer patients (one bladder, one breast, one lymphoma, one neuroendocrine tumor) during hematological recovery while receiving G-CSF for febrile neutropenia and one from one lymphoma patient at follow-up. Eight-two leukapheresis products were analyzed; 38 from 26 different breast cancer patients, 30 from 28 different patients with hematological malignancies (15 lymphoma, 11 myeloma, one chronic leukemia, one acute leukemia), three from three patients with testicular tumor, two from one patient with neuroendocrine malignancy, one from one patient with small cell lung cancer, eight from six different healthy donors for allografts.
The breast cancer patients, submitted to leukapheresis were stage II (with more than six involved axillary nodes) to IV. The mobilization regimen consisted of a cycle of FEC (5-fluorouracil 500 mg/m 2 , epirubicin 100 mg/m 2 , and cyclophosphamide 500 mg/m 2 ) and G-CSF (5-10 g/ kg/day). Patients with hematological malignancy were mobilized with 5 g/kg G-CSF, most of them after cyclophosphamide. Healthy donors were mobilized with 10 g/kg G-CSF.
One million peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood and leukapheresis samples by density-gradient centrifugation on FicollHypaque (Lymphoprep; Nycomed Pharma, Norway) before RNA extraction.
Cell lines
Three human breast carcinoma cell lines, MCF-7, BT-20 (both obtained from ATCC, Rockville, MD, USA) and CAMA-1 (provided by Amgen, Thousand Oaks, CA, USA) were cultured in DMEM 10% fetal calf serum (FCS). Sensitivity of tumor cell detection was tested on serial 10-fold dilutions of the three cell lines in 10 6 PBMC obtained from healthy donors to give tumor cell/PBMC ratios from 1/1 to 1/10 6 . For dilution of 1/10 6 , ten million cells were analyzed.
Peripheral blood mononuclear cell (PBMC) cultures with G-CSF
Four million PMBC obtained from seven healthy donors were cultured in 2 ml DMEM with 10% FCS in Petri culture dishes (Easy Grip 35 ϫ 10 mm; Becton Dickinson, Plymouth, UK) for 5 days with and without exogenous G-CSF at the concentration of 105 pg/ml. This concentration of G-CSF used for culture is close to the serum concentration of G-CSF observed in physiological conditions without exogenous administration. 20 
RT-PCR
Total cellular RNA was isolated from 10 6 cells using RNeasy Total RNA kit (Qiagen, Chatsworth, CA, USA) according to the manufacturer's instructions. To confirm RNA integrity, 5 l (10%) of the RNA preparation was run on 1% agarose gel stained with ethidium bromide.
One quarter of the total RNA from each sample was reverse transcribed (RT) in a 20 l reaction using the Superscript Preamplification System for First Strand cDNA Synthesis (Gibco, Gaithersburg, MD, USA) according to the manufacturer's instructions. Efficient first-strand cDNA synthesis was monitored for each sample by a control PCR amplification of the ␤2-microglobulin cDNA.
Muc-1 PCR was performed using the PCR protocol (primers, temperature and number of cycles) described by Noguchi et al. 19 CK19 nested PCR was performed according to Datta et al. 9 CEA PCR was performed using two different PCR protocols: hemi-nested CEA PCR described by Gerhard et al, 13 referred to as CEA(A) and CEA PCR described by Thompson et al, 21 referred to as CEA(B). Both primer sets have been claimed to be highly CEA-specific, spanning large intron sequences to avoid false positive results due to amplification of contaminating DNA ( Figure 1 ).
Two l of RT product were submitted to amplification in a 50 l reaction using 1 unit of Goldstar Taq Primers are listed in Table 1 . The PCR products were analyzed on 2% agarose gels by direct visualization after ethidium bromide staining.
Southern blot hybridization and colorimetric detection were performed on MCF7 dilution samples and on 10 patient samples with a digoxigenin-labeled CEA probe (DIG DNA labeling and detection kit; Boehringer Mannheim, Mannheim, Germany).
To avoid cross-contamination, RNA was extracted in a pre-PCR room, the manipulation of the first and second PCR products were performed in two other different rooms. The PCR reactions were run by series of at least eight samples to avoid the possibility of sporadic contamination. cDNA from the CAMA cell line was used as positive control and PCR mix without cDNA as negative control.
Immunocytochemistry (ICC)
Serial dilutions of the CAMA-1 cell line in PBMC, 13 blood samples from breast cancer patients (nine preoperative, four during adjuvant chemotherapy) and 14 leukapheresis samples (from eight breast cancer patients, five hematological patients and one allograft donor) were analyzed by ICC for detection of epithelial cells. A minimum of 2 ϫ 10 6 cells were spun or smeared on to poly-l-lysine coated slides. The slides were fixed in alcohol/acetone (1/1) for 2 min. Immunostaining was performed using anti-cytokeratin antibody (A45-B/B3; Micromet, Planegg-Martinsried, Germany) and anti-epithelial antigen antibody (BerEP4; DAKO, Glostrup, Denmark) (1/100 dilution) for 1 h, rabbit anti-mouse (DAKO 1/25 dilution) for 30 min, alkaline phosphatase-mouse anti-alkaline phosphatase (APAAP DAKO, 1/50 dilution) for 30 min, fast rednaphtol-DMF-levamisole 10 min and hematoxylin nuclear counterstain for 3 min. Tumor cells were identified by both immunocytochemical and morphological criteria. The latter included large nuclei, abnormal chromatin clumping and frequent clustering.
We did not perform ICC with anti-CEA antibody (clone A5B7; DAKO) because we had highly variable and heterogeneous staining on mammary cell lines in agreement with other reports. Figure 1 CEA PCR is tested using two different primer sets: CEA(A) and CEA(B). Both primer sets are claimed to be highly CEA-specific, spanning large intron sequences to avoid false positive results due to amplification of contaminating DNA. 
CEA RT-PCR on patient samples
Leukapheresis: A total of 36 of 38 (95%) leukapheresis samples from breast cancer patients were CEA(A) RT-PCR positive (Table 2 ). Since the CEA signal was strong on gel electrophoresis, no gain was observed by blotting and hybridization by a CEA probe. For this reason, only the first 10 patients' samples were submitted to blotting. Surprised by this very high positivity rate, leukapheresis samples from patients with malignancies other than breast cancer and from normal donors of PBSC were analyzed. Twenty-eight of 30 (93%) leukapheresis samples from patients with hematological malignancy and 100% of other leukapheresis samples were positive, including eight PBSC for allograft (Table 2) . Interestingly, while the leukapheresis product from one lymphoma patient was positive, his blood sample tested 6 weeks later was CEA negative.
Peripheral blood: Samples from 21 breast cancer patients before surgery were all CEA(A) RT-PCR negative, while four of 10 peripheral blood samples from breast cancer patients recently treated with chemotherapy were weakly positive. Three blood samples from four patients receiving G-CSF for febrile neutropenia were positive. Twenty-two leukapheresis and blood samples were submitted to CEA(B)-PCR. The results were concordant with the results obtained with protocol CEA(A) (Figure 2 ).
The signals of most PCR products of leukapheresis and peripheral blood from patients receiving G-CSF observed on agarose gels were much more intense than those obtained with MCF7 tumor cell/PBMC dilution 1/1000.
CEA RT-PCR on cell culture with G-CSF
In order to test the hypothesis of CEA induction by G-CSF in circulating hematological cells, PBMC from seven healthy individuals were incubated in medium alone or in the presence of exogenous G-CSF for 5 days. Five blood samples were RT-PCR positive for CEA(A) after 5 days of culture with G-CSF, while the same blood samples were CEA(A) RT-PCR negative in medium alone (Figure 3 ). For the two remaining individuals, one was negative in both conditions while the other was positive in both, the signal intensity of PCR product being stronger in cells cultured with G-CSF than without.
Immunocytochemistry
The ICC with anti-cytokeratin and anti-epithelial antigen antibodies gave a strong and homogenous staining of cells in the three breast cancer cell lines.
On serial dilution of the CAMA cell line, we obtained a reproducible sensitivity of one breast cancer cell detected in 10 6 normal PBMC, examining 3 ϫ 10 6 PBMC. Leukapheresis products from eight breast cancer patients, from five patients with hematological malignancy and from one allograft were examined. All were strongly CEA(A) RT-PCR positive. Tumor cells were seen in four breast can- Figure 2 RT-PCR product on 2% agarose gel with ethidium bromide staining for CEA(A), CEA(B) (first and second primer set) and ␤-2-microglobulin. There was no CEA signal in healthy controls and preoperative breast cancer patients. Leukapheresis products from two hematological patients (H1-2) and from two healthy donors for allograft (A1-2) had a strong positive signal in both PCR protocols. MCF7, breast cancer cell line.
cer samples and in one testicular cancer sample, while no circulating epithelial cells were found in the leukapheresis samples from patients with hematological malignancy and from allograft donors. Tumor cells were seen in two preoperative blood samples and no tumor cells were seen in the remaining preoperative and postoperative samples.
Discussion
The increasing use of autologous stem cell transplantation following high-dose chemotherapy in breast cancer increases concern about tumor cell contamination in autologous grafts. RT-PCR has been reported to be a powerful tool for tumor cell detection. We found CEA RT-PCR to cDNA ladder Control (-)  PBMC-1  PBMC-1G  PBMC-2  PBMC-2G   MCF7 131 bp CEA(A) Figure 3 Four million PBMC cultured with (PBMC 1-2 G) and without G-CSF (PBMC 1-2) . CEA expression appears in 5/7 samples cultured with G-CSF.
be highly specific in peripheral blood, but specificity was lost in samples from patients treated with G-CSF. CEA RT-PCR has been used for detection of micrometastases in gastro-intestinal, 13, 16, 17, [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] breast [13] [14] [15] [16] [17] [18] and lung 38 cancers. Specificity of the PCR protocol was tested on different healthy control tissues: peripheral blood, 16 ,17 bone marrow 13 and lymph nodes. 16, 17, 33 In order to preserve specificity, in some studies sensitivity had to be lowered.
17,32 Some authors describe a high level of CEA RT-PCR positive results in normal hematological tissues, 27, 39, 40 but their PCR protocol was different from that used in previous studies and was not validated by negative controls. It has been reported that skin contamination of the sample may lead to unexpected CEA transcripts. 18 Production of CEA has been found in exocrine sweat glands 41 and in keratinocytes in inflammatory skin reactions. 42 Jonas et al 37 prevented positive CEA RT-PCR in the blood of healthy controls using a cannula for venous puncture to prevent skin contamination. Positive results due to skin contamination are unlikely in our study, as no healthy controls were CEA RT-PCR positive.
We were confronted by an extremely high rate (95%) of CEA RT-PCR-positive apheresis products from breast cancer patients, much higher than that reported in previous studies. 7, 8 The PCR signals were strong, suggesting an important contamination by CEA-producing cells. However PCR positivity did not correlate with tumor cell detection by ICC.
This prompted us to test CEA expression in apheresis samples from patients without epithelial cancer and from healthy allograft donors. Here, CEA RT-PCR scored positive too, although no circulating epithelial cells could be demonstrated by ICC. Three of four patients receiving G-CSF for febrile neutropenia were CEA RT-PCR positive. Identical results were obtained with a second PCR protocol, using other CEA-specific primers, indicating that amplification of a gene other than CEA was unlikely.
These findings suggested that the administration of growth factors could influence expression of CEA in circulating non-epithelial cells, most probably hematological cells. This was confirmed by the induction of CEA expression in PBMC from healthy donors incubated with G-CSF, as demonstrated by CEA RT-PCR. The concentration of G-CSF we used in vitro can be found in physiological conditions. In granulocytopenia 43 and bacterial infections 20, 44 even higher serum concentrations are found due to increased endogenous production of G-CSF. Weak CEA expression, seen in four of 10 breast cancer patients during adjuvant chemotherapy after hematological recovery without growth factor support, could result from high endogenous production of G-CSF, after a period of leukopenia and high susceptibility to infections. Recently, Jung et al 45 found a 50% CEA positivity rate in patients with inflammatory bowel disease using a more sensitive nested CEA RT-PCR (35ϩ35 cycles).
Sensitivity of CEA RT-PCR tumor cell detection was reported to be high in most studies. Using two previously described highly sensitive CEA RT-PCR protocols we had poor sensitivity on three different breast cancer cell lines. The variability of CEA expression between different CEAproducing cell lines may account for these discrepancies. In the literature, sensitivity has been exclusively tested on serial dilutions of gastro-intestinal tumor cell lines. 13, 16, 17, 28, 34, 35 Jonas et al 33 demonstrated high expression variability between four different colorectal cancer cell lines. In mammary cancer, the serum level of CEA is a variable and poorly sensitive marker, much less reliable than in gastro-intestinal tumors. ICC with anti-CEA antibodies gives a variable and heterogeneous staining of mammary cancer cells. 16, 22 Extrapolation of RT-PCR sensitivity obtained in cell lines of one type of cancer to other cancers cannot be done.
The specificity of tumor cell detection by RT-PCR in carcinomas is based on amplification of genes that are present in non-malignant epithelial cells and presumed to be tissue-specific such as genes programming terminal cell differentiation. Lack of specificity has been reported for the most extensively RT-PCR tested genes in tumor cell detection. Amplification of pseudogenes or minimal illegitimate transcription is usually advocated for the lack of specificity. 26, 39, 46, 47, 48 Perhaps the induction of genes by environmental factors could be another frequent cause of unexpected gene transcription.
We showed CEA induction by G-CSF. Other studies have demonstrated a similar modulation of transcription of genes that are targeted by RT-PCR for tumor cell detection. It has been demonstrated that expression of cytokeratins 8, 18 and 19 45, 48 of PSA 49 and of mucin 50, 51 can be modulated by cytokines, steroids or environmental factors.
We conclude CEA RT-PCR cannot be recommended for tumor cell detection in patients receiving G-CSF and has to be interpreted with caution in inflammatory conditions or during hematological recovery due to loss of specificity and lack of sensitivity.
RT-PCR probably cannot be used to guide any clinical decision in epithelial cancers without gene transcripts from tumor-specific DNA rearrangements.
